股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF301 致： ...

Core Insights - The data indicates significant trading volume increases for various companies, suggesting heightened investor interest and potential market movements [1][2][3][4][5] Group 1: Companies with Notable Volume Increases - 阳光能源 (00757) reported a volume ratio of 2.35, indicating strong trading activity [2] - 长城汽车 (02333) had a volume ratio of 2.21, reflecting increased investor engagement [2] - 郑煤机 (00564) showed a volume ratio of 1.92, suggesting a notable rise in trading [2] Group 2: Additional Companies with Increased Trading Activity - 万国数据-SW (09698) recorded a volume ratio of 1.83, indicating significant market interest [2] - 映恩生物-B (09606) had a volume ratio of 1.78, reflecting heightened trading activity [2] - 超盈国际控股 (02111) reported a volume ratio of 1.71, suggesting increased investor focus [2] Group 3: Companies with Moderate Volume Ratios - 中国能源建设 (03996) had a volume ratio of 1.70, indicating a solid level of trading activity [2] - 亚信科技 (01675) reported a volume ratio of 1.60, reflecting moderate investor interest [2] - 金宝通 (00320) showed a volume ratio of 1.53, suggesting a rise in trading volume [2] Group 4: Companies with Lower Volume Ratios - 中国水务 (00855) had a volume ratio of 1.52, indicating stable trading activity [2] - 广汽集团 (02238) reported a volume ratio of 1.52, reflecting consistent investor engagement [2] - 凯莱英 (06821) showed a volume ratio of 1.52, suggesting steady trading interest [2]

Group 1 - The monitoring report from the Chinese CDC indicates an upward trend in the COVID-19 positive rate in April, with southern provinces showing higher rates than northern ones [1] - In Hong Kong, the COVID-19 positive rate increased from 1.71% to 8.21% over four weeks, indicating a rising trend in the region [1] - Taiwan reported a significant increase in emergency visits related to COVID-19, with a 66% rise in cases and additional severe cases and deaths [1] Group 2 - The Chinese CDC reported an increase in the COVID-19 positive rate among flu-like cases in emergency departments, rising from 7.5% to 16.2% [2] - Among hospitalized severe acute respiratory infection cases, the COVID-19 positive rate increased from 3.3% to 6.3% during the monitoring period [2] - The new coronavirus has surpassed rhinovirus as the leading cause of emergency visits for flu-like cases in the specified three-week period [2] Group 3 - Relevant pharmaceutical companies in the Hong Kong stock market include Shandong Xinhua Pharmaceutical (00719), Jinhongzi (06896), Sanofi (01530), and Dongyangguang Changjiang Pharmaceutical (01558) [3]

Group 1 - The stock price of Jinsongzi (06896.HK) closed at 4.350 HKD on April 28, marking a 3.82% increase from the previous trading day and reaching a one-year high [1] - The net capital inflow for the day was 2.7694 million HKD, with 3.65548 million HKD flowing in and 886.09 thousand HKD flowing out [1] - Jinsongzi Holdings Group Limited is recognized as an outstanding technology enterprise in the national pharmaceutical industry, originally established as Liuzhou Candy Factory in March 1956 [1] Group 2 - The company focuses on the pharmaceutical and food health industries, with over sixty types of products including Jinsongzi throat lozenges and various traditional foods [2] - Jinsongzi throat lozenges are well-regarded for their effectiveness in relieving throat discomfort and have maintained a leading market share in their category, exporting to over twenty countries and regions [2] - The company has achieved multiple certifications, including GMP, HACCP, ISO9001:2000, and FDA, establishing itself as a trusted unit in quality and consumer satisfaction in China [2]

Financial Performance - The group's revenue increased by approximately RMB 223.6 million or 23.3% to approximately RMB 1,185.0 million for the year ended December 31, 2024[12]. - Gross profit rose by approximately RMB 196.5 million or 28.2% to approximately RMB 894.2 million for the same period[12]. - Profit attributable to equity holders increased by approximately RMB 68.4 million or 27.3% to approximately RMB 318.6 million[12]. - The group's revenue for the year ended December 31, 2024, was approximately RMB 1,185.0 million, an increase of about RMB 223.6 million or 23.3% compared to RMB 961.4 million for the year ended December 31, 2023, primarily due to significant sales growth of the flagship product, Jinsongzi throat lozenges (OTC)[57]. - Revenue from the sales of Jinsongzi throat lozenges (OTC) for the year ended December 31, 2024, was approximately RMB 1,095.3 million, an increase of about RMB 230.4 million or 26.6% compared to RMB 864.9 million for the year ended December 31, 2023, driven by increased advertising and promotional activities[57]. - Net profit for the year ended December 31, 2024, was approximately RMB 318.6 million, an increase of approximately RMB 68.4 million or 27.3% compared to approximately RMB 250.2 million for the year ended December 31, 2023[70]. Product Development and Innovation - The company is advancing three major innovation tracks, including sugar-free solutions and patented probiotics lozenges[14]. - The group launched a new product, Jinsongzi compound probiotic lozenges, developed in collaboration with a research team, utilizing proprietary strains and advanced technologies[52]. - The company has developed a modern integrated group primarily engaged in the production and sales of lozenges, other pharmaceuticals, and biotechnology foods[27]. - Since 1994, the company has successfully developed 32 new products, including 8 pharmaceuticals and 22 food items, enhancing its R&D capabilities[41]. - The new product Jin Sang Zi compound probiotic lozenges, developed in collaboration with Beijing Agricultural University, utilizes advanced technologies and has obtained six patents[40]. Market Expansion and Strategy - The company expanded its international marketing network to cover over 60 countries and regions across six continents[18]. - The company officially entered the South Korean market in early 2025, launching customized product combinations[18]. - The company is focused on enhancing its core competitiveness and optimizing its product system based on consumer demand[85]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $30 million set aside for potential deals[7]. - The company aims to increase its market share by 3% in the next fiscal year through targeted marketing strategies[10]. Sales and Distribution - The flagship product, Golden Throat Lozenges (OTC), accounted for approximately 92.4% of the total revenue for the year ending December 31, 2024[31]. - The sales volume of Jinsongzi throat lozenges (OTC) reached 145,560 thousand boxes with a gross margin of 76.6% for the year ended December 31, 2024, compared to a sales volume of 118,133 thousand boxes and a gross margin of 74.8% for the previous year[59]. - The company has established a comprehensive national sales and distribution network, covering all provinces and regions in China, with significant revenue coming from distributors[45]. - As of December 31, 2024, Jin Sang Zi throat treasure products have been exported to 23 countries and regions, with new markets including India and South Korea[44]. Expenses and Financial Management - Selling and distribution expenses rose to approximately RMB 355.9 million for the year ended December 31, 2024, an increase of approximately RMB 89.5 million or 33.6% from approximately RMB 266.4 million for the year ended December 31, 2023, mainly due to increased promotional expenses[65]. - Administrative expenses increased to approximately RMB 117.1 million for the year ended December 31, 2024, up by approximately RMB 22.5 million or 23.8% from approximately RMB 94.6 million for the year ended December 31, 2023, primarily due to increased investment in R&D activities[66]. - The group's sales cost increased from approximately RMB 263.7 million for the year ended December 31, 2023, to approximately RMB 290.8 million for the year ended December 31, 2024, primarily due to the rise in sales volume of the OTC product Jinshanzui throat lozenges[60]. Corporate Governance and Shareholder Information - The board proposed a final dividend of HKD 0.5 per share, subject to shareholder approval[12]. - The company has adopted a stable dividend policy, prioritizing cash dividend distribution as a profit allocation goal[117]. - The company has confirmed the independence of all independent non-executive directors according to the criteria set out in Listing Rule 3.13[135]. - The company has established a compensation committee to develop its compensation policy based on operational performance and market practices[151]. - The company has confirmed compliance with the non-competition agreement with its controlling shareholders for the year ended December 31, 2024[171]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue increase of 10%[3]. - New product launches are expected to contribute an additional $50 million in revenue next quarter[4]. - The company aims to strengthen its leading position in the throat lozenge market and expand its market share in China's pharmaceutical and food sectors by 2025[85]. Related Party Transactions - The company has established related party transactions with its non-executive director, Jiang Peizhen, involving procurement and licensing agreements[172]. - The company has confirmed that all related party transactions comply with the disclosure requirements of the Listing Rules[196].

Financial Performance - The group's revenue increased by approximately RMB 223.6 million or 23.3% to approximately RMB 1,185.0 million for the year ended December 31, 2024[3]. - Gross profit rose by approximately RMB 196.5 million or 28.2% to approximately RMB 894.2 million for the same period[3]. - EBITDA increased by approximately RMB 78.3 million or 19.1% to approximately RMB 489.1 million[3]. - Profit attributable to equity holders increased by approximately RMB 68.4 million or 27.3% to approximately RMB 318.6 million[3]. - Total comprehensive income for the year was RMB 319.4 million, compared to RMB 254.8 million in the previous year[5]. - For the fiscal year ending December 31, 2024, the company's revenue was approximately RMB 1,185.0 million, an increase of about RMB 223.6 million or 23.3% compared to RMB 961.4 million for the fiscal year ending December 31, 2023[54]. - Net profit for the year ended December 31, 2024, was approximately RMB 318.6 million, an increase of approximately RMB 68.4 million or 27.3% compared to RMB 250.2 million in 2023[67]. Assets and Liabilities - Non-current assets totaled RMB 494.99 million, an increase from RMB 481.41 million in the previous year[6]. - Current assets amounted to RMB 1,756.18 million, a decrease from RMB 1,817.63 million in the previous year[6]. - Total liabilities decreased from RMB 706.89 million to RMB 700.47 million[6]. - The company's net assets decreased from RMB 1,550.70 million to RMB 1,466.30 million[7]. - The company's total borrowings increased to approximately RMB 426.9 million as of December 31, 2024, compared to RMB 412.3 million in 2023, reflecting an increase of RMB 14.6 million[69]. - The company's debt-to-equity ratio rose from approximately 26.6% as of December 31, 2023, to approximately 29.1% as of December 31, 2024[71]. Revenue Sources - Revenue from mainland China was RMB 1,178,108 thousand in 2024, up 24.0% from RMB 951,639 thousand in 2023[14]. - Revenue from a major customer (Customer A) accounted for RMB 148,375 thousand in 2024, an increase of 15.7% from RMB 128,285 thousand in 2023[16]. - Revenue from the sales of Jin Sangzi throat lozenges (OTC) for the fiscal year ending December 31, 2024, was approximately RMB 1,095.3 million, an increase of about RMB 230.4 million or 26.6% from RMB 864.9 million for the previous year[54]. - The flagship product, Jin Sangzi throat lozenges (OTC), accounted for approximately 92.4% of total revenue in the fiscal year ending December 31, 2024[37]. Expenses and Costs - Research and development costs rose to RMB 32,418 thousand in 2024, significantly higher than RMB 17,073 thousand in 2023, marking an increase of 90.1%[20]. - Total financial costs increased to RMB 15,363 thousand in 2024, up from RMB 10,699 thousand in 2023, representing a 43.5% rise[21]. - Income tax expense for 2024 was RMB 118,647 thousand, compared to RMB 110,859 thousand in 2023, indicating a 7.0% increase[22]. - Sales and distribution expenses increased to approximately RMB 355.9 million, a rise of approximately RMB 89.5 million or 33.6% from RMB 266.4 million in 2023, primarily due to increased promotional expenses[62]. - Administrative expenses rose to approximately RMB 117.1 million, an increase of approximately RMB 22.5 million or 23.8% from RMB 94.6 million in 2023, mainly due to higher investment in R&D activities[63]. Dividends - The board proposed a final dividend of HKD 0.5 per share, subject to approval at the upcoming annual general meeting[3]. - Proposed final dividend for 2024 is RMB 342,312 thousand, down from RMB 401,982 thousand in 2023, reflecting a decrease of 14.8%[22]. - The board proposes a final dividend of HKD 0.5 per share for the year ended December 31, 2024, subject to shareholder approval[85]. Product Development and Innovation - The company aims to leverage advanced technologies in product development, including patented probiotics and innovative encapsulation techniques[40]. - The new product "Jin Sang Zi Chang Bao" has passed testing and entered the Hong Kong market in March 2024[40]. - The company has received six patents for its active probiotics used in the newly developed Jin Sangzi compound probiotic lozenges, indicating a strong commitment to R&D[49]. - The company is focusing on developing new products such as gene drugs, traditional Chinese medicine formulas, and specialty health foods to drive growth in the health industry[53]. Market Strategy and Expansion - The company has established a comprehensive national sales and distribution network, covering all provinces and regions in China by December 31, 2024[45]. - The company has expanded its international strategy, with products exported to 23 countries and regions by December 31, 2024, including new markets like India and Korea[44]. - The company has developed a strong online presence, with nearly 100 million total views on its YouTube channel and over 4.5 million video views[44]. - The company has signed promotional cooperation agreements with 11 promoters to enhance local market penetration[47]. - The company plans to enhance its core competitiveness over the next decade by focusing on health services and expanding its market share in throat lozenges and other pharmaceutical products[79]. Corporate Governance and IPO - The company has adopted a corporate governance code to ensure high standards of governance and protect shareholder interests[86]. - The net proceeds from the initial public offering (IPO) after deducting underwriting fees and related expenses amount to approximately HKD 909.6 million[80]. - As of December 31, 2024, the company has utilized approximately HKD 731.3 million, representing about 80.4% of the IPO proceeds[80]. - The board will continuously evaluate the use of the net proceeds from the IPO to adapt to changing market conditions and improve performance[82].

Financial Performance - The group's revenue increased by approximately RMB 449 million or 9.4% to approximately RMB 5,245 million for the six months ended June 30, 2024[9]. - The group's gross profit rose by approximately RMB 297 million or 8.2% to approximately RMB 3,918 million for the same period[9]. - The group's EBITDA increased by approximately RMB 144 million or 7.9% to approximately RMB 1,956 million for the six months ended June 30, 2024[9]. - Profit attributable to equity holders of the company increased by approximately RMB 121 million or 9.9% to approximately RMB 1,342 million for the six months ended June 30, 2024[9]. - The group's net profit for the six months ended June 30, 2024, was approximately RMB 134.2 million, an increase of about RMB 12.1 million or 9.9% compared to RMB 122.1 million for the same period in 2023[71]. - The company's gross profit increased to approximately RMB 391.8 million, up by about RMB 29.7 million or 8.2% from RMB 362.1 million for the same period in 2023, with a gross margin of 74.7%[61]. - The company's net profit for the period was RMB 134,196,000, up 9.04% from RMB 122,144,000 in the previous year[118]. - Basic and diluted earnings per share increased to RMB 18.15 from RMB 16.52, representing a growth of 9.45%[118]. Revenue Breakdown - For the six months ended June 30, 2024, the sales revenue of the flagship product, Jinsongzi throat lozenges (OTC), accounted for approximately 91.2% of the total revenue[24]. - The sales revenue of the Jinsongzi throat treasure series products represented about 8.3% of the total revenue for the same period[27]. - The sales revenue from other products accounted for approximately 0.5% of the total revenue, including the newly launched Jinsongzi intestinal treasure, a prebiotic product[28]. - Revenue from the sales of Jin Sang Zi throat lozenges (OTC) was approximately RMB 478.4 million, an increase of about RMB 50.3 million or 11.7% compared to RMB 428.1 million for the same period in 2023[55]. - The sales revenue from Jin Sang Zi throat treasure series products was approximately RMB 43.3 million, a decrease of about RMB 5.9 million or 12.0% compared to RMB 49.2 million for the same period in 2023[55]. Product Development and Innovation - The company has successfully developed 35 new products since 1994, obtaining production licenses for these products, including 8 pharmaceuticals and 21 food items[31]. - The company launched a new product, Jinsongzi composite probiotics lozenges, developed in collaboration with Beijing Agricultural University, which has obtained six patents[28]. - The group has developed a new probiotic lozenge using proprietary strains and advanced technologies, securing six patents for its active probiotics[44]. - The group is committed to continuous innovation in developing new products, including gene drugs and traditional Chinese medicine, to drive the growth of China's health industry[48]. Market Expansion and Strategy - As of June 30, 2024, Jinsongzi throat lozenges (OTC) have been exported to five continents, including the USA, Canada, EU, Australia, Southeast Asia, Middle East, Mexico, Mongolia, and Africa[24]. - The Jinsongzi throat treasure series products have been exported to 23 countries and regions, with India being the latest addition in early 2024[26]. - The group has successfully signed agency agreements with all 10 ASEAN countries, exporting products to nine of them, excluding Laos[39]. - The company initiated an international communication strategy in 2023, achieving nearly 80 million total impressions on its YouTube channel and over 4 million video views[35]. - The group aims to strengthen its brand recognition and image in China, planning to increase advertising through broader internet media coverage[49]. - The group plans to continue optimizing its product system and enhancing organizational capabilities to maintain its leading position in the throat lozenge market and expand its market share in China's pharmaceutical and food sectors[48]. Financial Position and Investments - As of June 30, 2024, the group's total bank borrowings amounted to approximately RMB 512.0 million, an increase of about RMB 99.7 million or 24.2% from RMB 412.3 million as of December 31, 2023[75]. - The group's current assets net value as of June 30, 2024, was approximately RMB 810.0 million, down from RMB 1,110.7 million as of December 31, 2023[72]. - The group's debt-to-equity ratio increased from approximately 26.6% as of December 31, 2023, to about 39.9% as of June 30, 2024[77]. - The group plans to invest approximately RMB 76.3 million in the second phase of a new pharmaceutical production and R&D base in Liuzhou, Guangxi Zhuang Autonomous Region[87]. - The company is constructing a new production and R&D base in Guangxi, covering an area of approximately 60,000 square meters, which is expected to enhance production capacity for its throat lozenges[51]. Shareholder Information and Governance - The board of directors did not recommend the declaration of any interim dividend for the six months ended June 30, 2024[9]. - The board of directors holds a total of 516,013,700 shares, representing approximately 69.79% of the issued share capital as of June 30, 2024[103]. - Major shareholders, including family trusts, control approximately 61.28% of the company's issued shares, totaling 453,025,800 shares[111]. - The company has adopted a corporate governance code to ensure high standards of governance and accountability[96]. - The audit committee has reviewed the interim financial statements for the six months ending June 30, 2024, and found the existing risk management and internal control systems to be effective and adequate[100]. Cash Flow and Financial Metrics - The company's cash and cash equivalents decreased to RMB 990,249,000 from RMB 1,032,200,000, reflecting a decline of 4.1%[126]. - Operating cash flow for the six months ended June 30, 2024, was RMB 237,783,000, down from RMB 257,230,000 in the same period of 2023, a decrease of 7.6%[133]. - The net cash flow from operating activities for the first half of 2024 was RMB 237,783,000, a decrease of 7.5% compared to RMB 257,230,000 in the same period of 2023[136]. - The total comprehensive income for the period was RMB 135,627,000, compared to RMB 132,955,000 in the prior year, indicating a slight increase[121]. - The total income tax expense for the six months ended June 30, 2024, was RMB 35,799,000, an increase of 8.4% compared to RMB 33,033,000 for the same period in 2023[152].

Financial Performance - The group's revenue increased by approximately RMB 44.9 million or 9.4% to approximately RMB 524.5 million for the six months ended June 30, 2024, compared to the same period in 2023[2]. - Gross profit rose by approximately RMB 29.7 million or 8.2% to approximately RMB 391.8 million for the same period[2]. - EBITDA increased by approximately RMB 14.4 million or 7.9% to approximately RMB 195.6 million for the six months ended June 30, 2024[2]. - Profit attributable to equity holders of the company increased by approximately RMB 12.1 million or 9.9% to approximately RMB 134.2 million[2]. - Total comprehensive income for the period amounted to RMB 135.6 million, compared to RMB 132.9 million in the previous year[6]. - The company reported a basic and diluted earnings per share of RMB 18.15 for the six months ended June 30, 2024, compared to RMB 16.52 for the same period in 2023[4]. - The net profit for the period was RMB 122,144,000, contributing to a total comprehensive income of RMB 132,955,000, which includes a foreign exchange gain of RMB 10,811,000[11]. Assets and Liabilities - The total assets less current liabilities stood at RMB 1,293.0 million as of June 30, 2024, down from RMB 1,592.1 million at the end of 2023[8]. - The net asset value decreased to RMB 1,282.6 million as of June 30, 2024, compared to RMB 1,550.7 million at the end of 2023[8]. - For the six months ended June 30, 2023, the total equity amounted to RMB 1,428,873,000, a decrease from RMB 1,539,111,000 at the beginning of the year, reflecting a reduction of approximately 7.2%[11]. - Total bank loans due within one year amount to RMB 502,139,000, an increase from RMB 412,340,000 as of December 31, 2023, reflecting a significant rise in short-term borrowing[30]. - The company's debt-to-equity ratio increased from approximately 26.6% as of December 31, 2023, to approximately 39.9% as of June 30, 2024[69]. Cash Flow and Investments - Operating cash flow for the six months ended June 30, 2024, was RMB 237,783,000, a decrease of 7.6% compared to RMB 257,230,000 for the same period in 2023[13]. - The net cash used in investing activities was RMB 29,417,000, an improvement from RMB 37,979,000 in the previous year, suggesting more efficient capital allocation[13]. - New bank loans amounted to RMB 253,039,000, while the repayment of bank loans was RMB 153,340,000, indicating active management of financing activities[13]. - The cash and cash equivalents at the end of the period were RMB 939,076,000, an increase from RMB 842,603,000 year-over-year, reflecting a stronger liquidity position[13]. Product Development and Market Expansion - The company plans to continue expanding its product offerings in pharmaceuticals and health supplements, aiming for market growth in both domestic and international sectors[14]. - The flagship product, Jin Sangzi throat lozenges (OTC), accounted for approximately 91.2% of total revenue for the six months ending June 30, 2024[45]. - The company has successfully developed 35 new products since 1994, obtaining production licenses for these products[48]. - The company expanded its export markets, with Jin Sangzi throat lozenges (OTC) now available in major regions including the US, Canada, EU, Australia, Southeast Asia, Middle East, Mexico, Mongolia, and Africa[45]. - The company is collaborating with Beijing Agricultural University on the development of a new probiotic lozenge, which has received six patents[47]. Marketing and Brand Strategy - The company aims to strengthen its brand recognition and market presence through increased advertising and targeted marketing strategies[54]. - The company has established partnerships with 11 promoters to enhance product marketing in local markets[51]. - The company's YouTube channel has achieved nearly 80 million total impressions and over 4 million video views as of the announcement date[49]. Corporate Governance and Future Plans - The company has adopted a corporate governance code to ensure high standards of governance and protect shareholder interests[77]. - The company plans to invest approximately RMB 76.3 million to construct a new pharmaceutical production and R&D base in Liuzhou, Guangxi Zhuang Autonomous Region as part of its future plans[72]. - The unutilized IPO proceeds are expected to be fully utilized by 2028[77].

Financial Performance - The group's revenue decreased by approximately RMB 30.6 million or 3.1% to approximately RMB 961.4 million for the year ended December 31, 2023[2]. - Gross profit fell by about RMB 23.2 million or 3.2% to approximately RMB 697.7 million compared to the previous year[2]. - EBITDA decreased by approximately RMB 14.1 million or 3.3% to approximately RMB 410.8 million for the year ended December 31, 2023[2]. - Profit attributable to equity holders of the company decreased by approximately RMB 31.0 million or 11.0% to approximately RMB 250.2 million[2]. - Total revenue for 2023 was RMB 961,377 thousand, a decrease from RMB 992,014 thousand in 2022, representing a decline of approximately 3.1%[18]. - The company recognized revenue from contracts with customers of RMB 961,377 thousand in 2023, down from RMB 991,866 thousand in 2022, a decrease of about 3.1%[18]. - Revenue from the sales of the flagship product, Jinsongzi throat lozenges (OTC), was approximately RMB 864.9 million for the year ended December 31, 2023, down RMB 39.7 million or 4.4% from RMB 904.6 million in the previous year[45]. - Revenue from the sales of the Jinsongzi throat treasure series products increased by approximately RMB 10.2 million or 12.5%, reaching RMB 91.6 million for the year ended December 31, 2023, due to expanded sales channels[45]. - Net profit for the year ended December 31, 2023, was approximately RMB 250.2 million, a decrease of about RMB 31.0 million or 11.0% compared to RMB 281.2 million for the year ended December 31, 2022[56]. Assets and Liabilities - Total current assets increased to RMB 1,817.6 million from RMB 1,794.7 million year-on-year[7]. - Current liabilities decreased to RMB 706.9 million from RMB 734.6 million year-on-year[7]. - Net current assets increased to RMB 1,110.7 million from RMB 1,060.1 million year-on-year[7]. - Total assets less current liabilities increased to RMB 1,592.1 million from RMB 1,564.7 million year-on-year[9]. - Total equity attributable to equity holders of the parent increased to RMB 1,550.7 million from RMB 1,539.1 million year-on-year[10]. - Trade receivables and notes receivable amounted to RMB 422,344,000 in 2023, a decrease from RMB 620,338,000 in 2022, showing a decline of 31.9%[25]. - The net book value of trade receivables was RMB 419,662,000 in 2023, down from RMB 618,698,000 in 2022, indicating a decrease of 32.2%[25]. - Trade payables totaled RMB 17,527,000 in 2023, down from RMB 25,313,000 in 2022, reflecting a decrease of 30.8%[27]. - The total interest-bearing bank and other borrowings amounted to RMB 412,340,000 in 2023, compared to RMB 272,586,000 in 2022, indicating an increase of 51.4%[28]. Expenses and Income - The cost of sales for 2023 was RMB 263,658 thousand, compared to RMB 271,094 thousand in 2022, indicating a reduction of approximately 2.7%[20]. - Research and development expenses rose significantly to RMB 17,073 thousand in 2023 from RMB 6,420 thousand in 2022, marking an increase of 165.5%[20]. - Other income and gains totaled RMB 39,291 thousand in 2023, up from RMB 24,687 thousand in 2022, representing a growth of 59.3%[19]. - The total tax expense for the year was RMB 110,859,000, up from RMB 94,775,000 in 2022, indicating a year-over-year increase of 16.9%[23]. - Selling and distribution expenses decreased to approximately RMB 266.4 million for the year ended December 31, 2023, down from approximately RMB 279.0 million for the year ended December 31, 2022, a decrease of about RMB 12.6 million or 4.5%[51]. - Administrative expenses increased to approximately RMB 94.6 million for the year ended December 31, 2023, up from approximately RMB 78.6 million for the year ended December 31, 2022, an increase of about RMB 16.0 million or 20.4%[52]. Dividends and Shareholder Information - The board proposed a final dividend of HKD 0.6 per share, subject to approval at the upcoming annual general meeting[2]. - The proposed final dividend per ordinary share increased to HKD 0.60 in 2023 from HKD 0.36 in 2022, reflecting a growth of 66.7%[23]. - The group has not made any significant investments or acquisitions of subsidiaries, associates, or joint ventures as of December 31, 2023[60]. - The board of directors includes non-executive director Ms. Jiang Peizhen and executive directors Mr. Zeng Yong, Mr. Huang Jianping, Mr. Zeng Kexiong, and Mr. He Jinqiang[72]. - Independent non-executive directors include Mr. Li Hua, Mr. Zhu Xiarong, and Mr. Cheng Yiqun[72]. Market Position and Product Development - The flagship product, Jin Sangzi throat lozenges, received multiple awards in 2023, enhancing the brand's market position[31]. - The company has developed into a modern conglomerate primarily engaged in the production and sale of throat lozenges, other pharmaceuticals, and biotechnology foods[31]. - The sales revenue of the company's main product, Jin Sang Zi Throat Lozenges (OTC), accounted for approximately 90.0% of total revenue for the year ended December 31, 2023[33]. - The sales revenue of the Jin Sang Zi Throat Treasure series products accounted for about 9.5% of total revenue for the year ended December 31, 2023[33]. - Other products, including Ginkgo Biloba tablets and the new product Jin Sang Zi Intestinal Treasure, accounted for approximately 0.5% of total revenue for the year ended December 31, 2023[34]. - The new product Jin Sang Zi Intestinal Treasure has passed relevant testing and has entered the Hong Kong market as of March 2024[34]. - The company has successfully developed 32 new products since 1994, including 8 pharmaceuticals and 22 food products, with production licenses obtained for these products[36]. - The company is collaborating with Beijing Agricultural University to develop a new probiotic lozenge using proprietary strains, which has obtained six patents and employs advanced technologies[41]. - The company plans to enhance its production capacity by constructing a new pharmaceutical production and R&D base in Liuzhou, Guangxi, covering an area of approximately 60,000 square meters[44]. - The second phase of the new base is expected to cover about 50,000 square meters and will focus on developing health-related products, including gene drugs and traditional Chinese medicine[44]. - The company aims to strengthen its brand recognition and market presence by increasing advertising through broader internet media coverage[43]. - The company is committed to continuous innovation in product development, particularly in the probiotic market, which is gaining acceptance among consumers[41]. - The company has noted a significant increase in consumer spending on health-related products, driven by heightened health awareness post-pandemic[41]. - The company is focusing on a "single brand, multiple categories, and multi-channel" development strategy to enhance its operational capabilities and market competitiveness[43]. Employment and Costs - As of December 31, 2023, the group employed a total of 869 full-time employees, an increase from 853 full-time employees as of December 31, 2022[59]. - Employee costs for the year ended December 31, 2023, were approximately RMB 82.5 million, compared to RMB 80.4 million for the same period in 2022, reflecting a year-on-year increase of 2.6%[59]. Future Plans and Investments - The group plans to invest approximately RMB 94.3 million in the second phase of a new pharmaceutical production and R&D base in Liuzhou, Guangxi Zhuang Autonomous Region[61]. - The group aims to strengthen its leading position in the throat lozenge market and expand its market share in China's pharmaceutical and food sectors in 2024[63]. - The group is committed to enhancing production capacity, expanding its product portfolio, and improving R&D capabilities to promote synergy among different product segments[63]. - The group has begun underground construction for the food production plant and R&D center project as of December 31, 2023[65]. - The unutilized proceeds from the initial public offering are expected to be fully utilized by 2028[66]. - The group has utilized approximately HKD 683.62 million of the net proceeds from its initial public offering, accounting for about 75.16% of the total proceeds[64].

Financial Performance - The group's revenue increased by approximately RMB 167.5 million or 53.7% to approximately RMB 479.6 million for the six months ended June 30, 2023, compared to the same period in 2022[12] - The group's gross profit rose by approximately RMB 135.0 million or 59.5% to approximately RMB 362.1 million for the same period[12] - EBITDA increased by approximately RMB 82.1 million or 82.8% to approximately RMB 181.2 million for the six months ended June 30, 2023[12] - Profit attributable to equity holders increased by approximately RMB 65.4 million or 115.3% to approximately RMB 122.1 million for the same period[12] - For the six months ended June 30, 2023, the company's revenue was approximately RMB 479.6 million, an increase of about RMB 167.5 million or 53.7% compared to RMB 312.1 million for the same period in 2022[31] - Revenue from the sales of Golden Throat lozenges (OTC) was approximately RMB 428.1 million, up RMB 149.0 million or 53.4% from RMB 279.1 million in the prior year[31] - The gross profit for the six months ended June 30, 2023, increased to approximately RMB 362.1 million, a rise of about RMB 135.0 million or 59.5% from RMB 227.1 million in the same period of 2022, with a gross margin of 75.5%[35] - Net profit for the six months ended June 30, 2023, was approximately RMB 122.1 million, an increase of about RMB 65.4 million or 115.3% compared to RMB 56.7 million for the same period in 2022[42] - The company achieved a profit before tax of RMB 155,177,000, which is a 105.5% increase compared to RMB 75,639,000 in the previous year[68] - The company reported a total comprehensive income of RMB 132,955,000 for the period, significantly higher than RMB 58,768,000 in the previous year[71] Market and Product Development - The company is a leading manufacturer of throat lozenges in China, with a history dating back to 1956[7] - The company focuses on the production and sale of throat lozenges and other pharmaceuticals and food products[7] - The company aims to expand its market presence and enhance product offerings in the future[12] - The group has a strong commitment to research and development for new products and technologies[12] - For the six months ended June 30, 2023, the sales revenue of Golden Throat Holdings Group was approximately 89.2% from its flagship product, Golden Throat Lozenges (OTC) [19] - The sales revenue from the Golden Throat Lozenges (OTC) increased compared to the same period in 2022, reflecting a continued growth trend in market demand post-COVID-19 [18] - The Golden Throat Lozenges (OTC) have been exported to five continents, including the USA, Canada, EU, Australia, Southeast Asia, Middle East, Mexico, Mongolia, and Africa as of June 30, 2023 [19] - The Golden Throat Treasure series products accounted for approximately 10.3% of total revenue for the six months ended June 30, 2023, with exports to 22 countries and regions [20] - The company has developed 35 new products since 1994, with 8 classified as pharmaceuticals and 21 as food products, showcasing its strong R&D capabilities [22] - New products include Golden Throat Probiotic Tablets, developed in collaboration with Beijing Agricultural University, targeting the Chinese market's need for domestically developed probiotics [21] - The company plans to enhance its product offerings and market share in the throat lozenge sector while continuing to innovate in gene drugs, traditional Chinese medicine, and health foods[29] Operational Efficiency and Expansion - The company completed the relocation to a new drug production and R&D base in Liuzhou, Guangxi, with a total area of approximately 60,000 square meters, enhancing production efficiency and product quality[30] - The second phase of the new base, covering 48 acres and expected to have a built-up area of about 50,000 square meters, is planned to start construction by the end of Q3 2023[30] - The company has established a comprehensive national sales and distribution network covering all provinces, autonomous regions, and municipalities in China as of June 30, 2023 [24] - The company continues to expand its market presence by strengthening partnerships with key distributors and chain pharmacies in 2023 [24] - The company is expanding its online sales channels, including the WeChat mini-program launched in early 2020, anticipating breakthroughs in e-commerce[29] - The company aims to strengthen its brand recognition and image in China, promoting its Golden Throat brand as a household name for effective and safe throat lozenges[29] - The company will increase advertising through broader internet media coverage to enhance market promotion and collaboration with distributors for targeted marketing activities[29] Financial Position and Management - As of June 30, 2023, the group's current assets net value was approximately RMB 938.9 million, down from RMB 1,060.1 million as of December 31, 2022[43] - Total interest-bearing bank loans and other borrowings as of June 30, 2023, were approximately RMB 261.0 million, a decrease of about RMB 11.6 million or 4.3% from RMB 272.6 million as of December 31, 2022[44] - The debt-to-equity ratio increased from approximately 17.7% as of December 31, 2022, to about 18.3% as of June 30, 2023[45] - The group employed a total of 860 full-time employees as of June 30, 2023, down from 937 full-time employees as of June 30, 2022[47] - The company reported a net cash flow from operating activities for the six months ended June 30, 2023, of RMB 257,230,000, representing a significant increase from RMB 124,926,000 in the same period of 2022[76] - The total liabilities decreased to RMB 1,223,218,000 as of June 30, 2023, compared to RMB 1,469,300,000 at the end of 2022, reflecting a reduction of 16.8%[73] - The company's cash and cash equivalents stood at RMB 895,958,000, slightly up from RMB 895,515,000 at the end of 2022[73] - The total equity attributable to owners of the parent company was RMB 1,428,873,000, down from RMB 1,539,111,000, marking a decrease of 7.2%[74] - The company declared a dividend of RMB 243,193,000 for the year-end 2022, impacting the retained earnings[75] Corporate Governance and Compliance - The company has complied with all applicable provisions of the corporate governance code during the six months ending June 30, 2023[54] - The board believes that existing risk management and internal control systems are effective and adequate[57] - The company has not granted any share options under its share option scheme since its adoption in June 2017[63] - There were no changes in the information of directors and senior management that required disclosure since the last annual report[67] Related Party Transactions - The company engaged in related party transactions with Guangxi Changbao Biotechnology Co., Ltd., purchasing products worth RMB 2,227,000 during the six months ended June 30, 2023, compared to RMB 363,000 in the same period of 2022, representing a significant increase[97] - The outstanding balance receivable from related parties was RMB 2,671,000 as of June 30, 2023, up from RMB 510,000 as of December 31, 2022[98] - The outstanding balance payable to a director was RMB 2,533,000 as of June 30, 2023, compared to RMB 236,000 as of December 31, 2022[98] - The outstanding balance payable to related parties was RMB 870,000 as of June 30, 2023, slightly up from RMB 867,000 as of December 31, 2022[98]